12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CM-AT: Phase III data

Curemark reported top-line data from a double-blind, U.S. Phase III trial in 170 autistic patients aged 3-8 showing that thrice-daily CM-AT for 90 days met the primary and secondary endpoints vs....

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >